141 related articles for article (PubMed ID: 8961085)
1. Modification of the cardiovascular effects of ephedrine by the reversible monoamine oxidase A-inhibitor moclobemide.
Dingemanse J; Guentert T; Gieschke R; Stabl M
J Cardiovasc Pharmacol; 1996 Dec; 28(6):856-61. PubMed ID: 8961085
[TBL] [Abstract][Full Text] [Related]
2. Simultaneous inhibition of catechol-O-methyltransferase and monoamine oxidase A: effects on hemodynamics and catecholamine metabolism in healthy volunteers.
Illi A; Sundberg S; Ojala-Karlsson P; Scheinin M; Gordin A
Clin Pharmacol Ther; 1996 Apr; 59(4):450-7. PubMed ID: 8612391
[TBL] [Abstract][Full Text] [Related]
3. Comparative investigation of the effect of moclobemide and toloxatone on monoamine oxidase activity and psychometric performance in healthy subjects.
Dingemanse J; Berlin I; Payan C; Thiede HM; Puech AJ
Psychopharmacology (Berl); 1992; 106 Suppl():S68-70. PubMed ID: 1546145
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the monoamine oxidase inhibiting properties of two reversible and selective monoamine oxidase-A inhibitors moclobemide and toloxatone, and assessment of their effect on psychometric performance in healthy subjects.
Berlin I; Zimmer R; Thiede HM; Payan C; Hergueta T; Robin L; Puech AJ
Br J Clin Pharmacol; 1990 Dec; 30(6):805-16. PubMed ID: 1705137
[TBL] [Abstract][Full Text] [Related]
5. Tyramine pharmacodynamics during combined administration of lazabemide and moclobemide.
Dingemanse J; Hussain Y; Korn A
Int J Clin Pharmacol Ther; 1996 Apr; 34(4):172-7. PubMed ID: 8861736
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic-pharmacodynamic interactions between two selective monoamine oxidase inhibitors: moclobemide and selegiline.
Dingemanse J; Kneer J; Wallnöfer A; Kettler R; Zürcher G; Koulu M; Korn A
Clin Neuropharmacol; 1996 Oct; 19(5):399-414. PubMed ID: 8889283
[TBL] [Abstract][Full Text] [Related]
7. Relationship between tyramine potentiation and monoamine oxidase (MAO) inhibition: comparison between moclobemide and other MAO inhibitors.
Zimmer R
Acta Psychiatr Scand Suppl; 1990; 360():81-3. PubMed ID: 2248084
[TBL] [Abstract][Full Text] [Related]
8. Cardiocirculatory effects of moclobemide (Ro 11-1163), a new reversible, a short-acting MAO-inhibitor with preferential type A inhibition, in healthy volunteers and depressive patients.
Gasic S; Korn A; Eichler HG; Oberhummer I; Zapotoczky HG
Eur J Clin Pharmacol; 1983; 25(2):173-7. PubMed ID: 6628500
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the effects of moclobemide and selegiline on tyramine-evoked mydriasis in man.
Bitsios P; Langley RW; Tavernor S; Pyykkö K; Scheinin M; Szabadi E; Bradshaw CM
Br J Clin Pharmacol; 1998 Jun; 45(6):551-8. PubMed ID: 9663810
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of oral moclobemide in healthy human subjects and effects on MAO-activity in platelets and excretion of urine monoamine metabolites.
Wiesel FA; Raaflaub J; Kettler R
Eur J Clin Pharmacol; 1985; 28(1):89-95. PubMed ID: 3987791
[TBL] [Abstract][Full Text] [Related]
11. The advent of a new generation of monoamine oxidase inhibitor antidepressants: pharmacologic studies with moclobemide and brofaromine.
Lavian G; Finberg JP; Youdim MB
Clin Neuropharmacol; 1993; 16 Suppl 2():S1-7. PubMed ID: 8313392
[TBL] [Abstract][Full Text] [Related]
12. The effects of moclobemide on the pharmacokinetics of the 5-HT1B/1D agonist rizatriptan in healthy volunteers.
Van Haarst AD; Van Gerven JM; Cohen AF; De Smet M; Sterrett A; Birk KL; Fisher AL; De Puy ME; Goldberg MR; Musson DG
Br J Clin Pharmacol; 1999 Aug; 48(2):190-6. PubMed ID: 10417495
[TBL] [Abstract][Full Text] [Related]
13. Clinical pharmacology of moclobemide during chronic administration of high doses to healthy subjects.
Dingemanse J; Wood N; Guentert T; Oie S; Ouwerkerk M; Amrein R
Psychopharmacology (Berl); 1998 Nov; 140(2):164-72. PubMed ID: 9860107
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the pressor effect of tyramine after treatment with phenelzine and moclobemide in healthy male volunteers.
Simpson GM; Gratz SS
Clin Pharmacol Ther; 1992 Sep; 52(3):286-91. PubMed ID: 1526086
[TBL] [Abstract][Full Text] [Related]
15. Monoamine oxidase-A: pharmacodynamics in humans of moclobemide, a reversible and selective inhibitor.
Holford NH; Guentert TW; Dingemanse J; Banken L
Br J Clin Pharmacol; 1994 May; 37(5):433-9. PubMed ID: 7519866
[TBL] [Abstract][Full Text] [Related]
16. Effect of a novel monoamine-oxidase inhibitor, moclobemide on the sensitivity to intravenous tyramine and norepinephrine in humans.
Cusson JR; Goldenberg E; Larochelle P
J Clin Pharmacol; 1991 May; 31(5):462-7. PubMed ID: 2050833
[TBL] [Abstract][Full Text] [Related]
17. Epidural anaesthesia, ephedrine and phenylephrine in a patient taking moclobemide, a new monoamine oxidase inhibitor.
Martyr JW; Orlikowski CE
Anaesthesia; 1996 Dec; 51(12):1150-2. PubMed ID: 9038453
[TBL] [Abstract][Full Text] [Related]
18. Interaction of moclobemide, a new reversible monoamine oxidase inhibitor with oral tyramine.
Gieschke R; Schmid-Burgk W; Amrein R
J Neural Transm Suppl; 1988; 26():97-104. PubMed ID: 3283292
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of monoamine oxidase by moclobemide: effects on monoamine metabolism and secretion of anterior pituitary hormones and cortisol in healthy volunteers.
Koulu M; Scheinin M; Kaarttinen A; Kallio J; Pyykkö K; Vuorinen J; Zimmer RH
Br J Clin Pharmacol; 1989 Feb; 27(2):243-55. PubMed ID: 2469451
[TBL] [Abstract][Full Text] [Related]
20. Influence of food on the tyramine pressor effect during chronic moclobemide treatment of healthy volunteers.
Audebert C; Blin O; Monjanel-Mouterde S; Auquier P; Pedarriosse AM; Dingemanse J; Durand A; Cano JP
Eur J Clin Pharmacol; 1992; 43(5):507-12. PubMed ID: 1483487
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
